Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
Charlotte K.Y. Ng(Humanitas University), Jorge S. Reis‐Filho(AstraZeneca (France))
Cited by 135
Related Papers
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma
|Science Translational Medicine|2011|401
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|Annals of Oncology|2023|298